SFTPC-Related Interstitial Lung Disease: A Patient Guide

Interstitial lung disease (ILD) due to surfactant protein C (SP-C) deficiency—often called SFTPC-related ILD—is a rare genetic condition that fundamentally changes how the lungs process and maintain the delicate air sacs responsible for breathing. It is caused by a mutation in the SFTPC gene, which provides the instructions for making a protein that is vital for keeping these air sacs open. When this gene is mutated, the body produces a “misfolded” or broken version of the protein that can become toxic to the lung cells, leading to a cycle of inflammation and, in some cases, permanent scarring known as fibrosis ^[1][2][3]. Not every carrier develops disease, and mechanisms can be variant-dependent.

Because the condition is so rare, its exact prevalence in the general population is unknown, but it is recognized as a significant cause of genetic lung disease across the lifespan. One of the most striking features of this condition is its extreme variability; it does not follow a single, predictable path. A mutation in the SFTPC gene might cause severe respiratory distress in a newborn, or it might not cause noticeable symptoms until a person reaches adulthood. Even within the same family, individuals carrying the exact same genetic “spelling error” may experience vastly different levels of health and stability ^[4][5][6].

Reaching a definitive diagnosis has been transformed by modern medicine, moving away from invasive surgeries and toward genetic testing. Identifying a pathogenic or likely pathogenic variant in the SFTPC gene through DNA sequencing is now a primary way doctors support the diagnosis when the clinical picture is compatible. This genetic clarity is essential not only for managing the patient’s health but also for helping families understand whether the mutation was inherited or occurred spontaneously for the first time ^[7][8]. However, a variant of uncertain significance (VUS) must not be treated as diagnostic, and diagnosis is always integrated with clinical assessment.

Daily life with this condition focuses on comprehensive supportive care and vigilant monitoring. Because there is currently no targeted cure that repairs the genetic mutation, the “standard of care” involves protecting the lungs through individualized measures like oxygen therapy for documented hypoxemia, nutritional support when growth is affected to fuel the body’s extra work of breathing, and an individualized infection prevention plan. While some medications are used “off-label” to try and reduce lung inflammation, their effectiveness varies significantly from person to person. The goal of every management plan is to maintain the best possible lung function and quality of life while working closely with a specialized medical team to navigate the road ahead ^[8][9].